Hepatitis C therapy in 2011: is less more, is more less?

Braz J Infect Dis. 2011 Nov-Dec;15(6):508-12. doi: 10.1016/s1413-8670(11)70243-4.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antiviral Agents / administration & dosage*
  • Antiviral Agents / adverse effects
  • Drug Therapy, Combination
  • Hepatitis C / drug therapy*
  • Humans
  • Oligopeptides / administration & dosage*
  • Oligopeptides / adverse effects
  • Proline / administration & dosage
  • Proline / adverse effects
  • Proline / analogs & derivatives*
  • Protease Inhibitors / administration & dosage*
  • Protease Inhibitors / adverse effects

Substances

  • Antiviral Agents
  • Oligopeptides
  • Protease Inhibitors
  • telaprevir
  • N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
  • Proline